WEKO3
アイテム
{"_buckets": {"deposit": "22a3c299-b5c2-4da5-943c-95f841989f4e"}, "_deposit": {"created_by": 14, "id": "14135", "owners": [14], "pid": {"revision_id": 0, "type": "depid", "value": "14135"}, "status": "published"}, "_oai": {"id": "oai:sapmed.repo.nii.ac.jp:00014135", "sets": ["1856"]}, "author_link": ["23139", "23138"], "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1-6", "bibliographicPageEnd": "17", "bibliographicPageStart": "13", "bibliographicVolumeNumber": "84", "bibliographic_titles": [{"bibliographic_title": "札幌医学雑誌 = The Sapporo medical journal"}, {"bibliographic_title": "The Sapporo medical journal", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Interstitial pneumonia (IP) is a general category that includes many different pulmonary conditions based on inflammation and fibrosis in the lung. Idiopathic pulmonary fibrosis (IPF), a subtype of idiopathic interstitial pneumonias (IIPs), is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause. IIPs including IPF became specified as an incurable disease by Japanese Ministry of Health, Labour and Welfare. To clarify the actual situation in their epidemiology, we carried out a large-scale cohort study in Hokkaido. The current status of IPF in Japan was characterized for the first time through our study. Surfactant protein (SP)-A and SP-D which are serologic markers developed by our university-industry research collaboration are adopted in diagnostic criteria for IIPs which the ministry established. In new treatment, Pirfenidone having anti-fibrotic effect was developed and authorized as an orphan drug of IPF by multicentral-clinical trial in which our department took an important role. The use of the new drug will improve prognosis of IPF in the near future.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "23139", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Hiroki, TAKAHASHI"}]}]}, "item_7_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.15114/smj.84.13", "subitem_identifier_reg_type": "JaLC"}]}, "item_7_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "札幌医科大学医学部"}]}, "item_7_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0036-472X", "subitem_source_identifier_type": "ISSN"}]}, "item_7_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "高橋, 弘毅"}], "nameIdentifiers": [{"nameIdentifier": "23138", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-07-13"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "n0036472x84113.pdf", "filesize": [{"value": "1.4 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 1400000.0, "url": {"label": "n0036472x84113.pdf", "url": "https://sapmed.repo.nii.ac.jp/record/14135/files/n0036472x84113.pdf"}, "version_id": "6030e2ad-214c-4088-aee4-5bc667d8cb53"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "interstitial pneumonia", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "idiopathic pulmonary fibrosis", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "surfactant protein-A", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "surfactant protein-D", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "anti-fibrotic drug", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "間質性肺炎とサーファクタント蛋白質", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "間質性肺炎とサーファクタント蛋白質", "subitem_title_language": "ja"}, {"subitem_title": "Interstitial pneumonia and surfactant proteins", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "14", "path": ["1856"], "permalink_uri": "https://doi.org/10.15114/smj.84.13", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2019-07-13"}, "publish_date": "2019-07-13", "publish_status": "0", "recid": "14135", "relation": {}, "relation_version_is_last": true, "title": ["間質性肺炎とサーファクタント蛋白質"], "weko_shared_id": -1}
間質性肺炎とサーファクタント蛋白質
https://doi.org/10.15114/smj.84.13
https://doi.org/10.15114/smj.84.13de3545f8-ccec-4474-aa89-9b87107a1036
名前 / ファイル | ライセンス | アクション |
---|---|---|
n0036472x84113.pdf (1.4 MB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-07-13 | |||||
タイトル | ||||||
言語 | ja | |||||
タイトル | 間質性肺炎とサーファクタント蛋白質 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Interstitial pneumonia and surfactant proteins | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | interstitial pneumonia | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | idiopathic pulmonary fibrosis | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | surfactant protein-A | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | surfactant protein-D | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | anti-fibrotic drug | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
ID登録 | ||||||
ID登録 | 10.15114/smj.84.13 | |||||
ID登録タイプ | JaLC | |||||
著者 |
高橋, 弘毅
× 高橋, 弘毅 |
|||||
著者別名 | ||||||
姓名 | Hiroki, TAKAHASHI | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Interstitial pneumonia (IP) is a general category that includes many different pulmonary conditions based on inflammation and fibrosis in the lung. Idiopathic pulmonary fibrosis (IPF), a subtype of idiopathic interstitial pneumonias (IIPs), is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause. IIPs including IPF became specified as an incurable disease by Japanese Ministry of Health, Labour and Welfare. To clarify the actual situation in their epidemiology, we carried out a large-scale cohort study in Hokkaido. The current status of IPF in Japan was characterized for the first time through our study. Surfactant protein (SP)-A and SP-D which are serologic markers developed by our university-industry research collaboration are adopted in diagnostic criteria for IIPs which the ministry established. In new treatment, Pirfenidone having anti-fibrotic effect was developed and authorized as an orphan drug of IPF by multicentral-clinical trial in which our department took an important role. The use of the new drug will improve prognosis of IPF in the near future. | |||||
書誌情報 |
札幌医学雑誌 = The Sapporo medical journal en : The Sapporo medical journal 巻 84, 号 1-6, p. 13-17, 発行日 2015-12 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0036-472X | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | 札幌医科大学医学部 |